On Oct 25, major Wall Street analysts update their ratings for $Intellia Therapeutics (NTLA.US)$, with price targets ranging from $18 to $90.
Morgan Stanley analyst Terence Flynn maintains with a buy rating, and maintains the target price at $57.
BofA Securities analyst Alec Stranahan initiates coverage with a buy rating, and sets the target price at $65.
Barclays analyst Gena Wang maintains with a buy rating, and maintains the target price at $76.
Baird analyst Jack Allen maintains with a hold rating, and adjusts the target price from $24 to $18.
Oppenheimer analyst Jay Olson maintains with a buy rating, and maintains the target price at $70.
Furthermore, according to the comprehensive report, the opinions of $Intellia Therapeutics (NTLA.US)$'s main analysts recently are as follows:
The latest data from Intellia Therapeutics' NTLA-2002 Phase 2 trial for HAE, presented at EAACI in June, indicated an attack reduction that was less striking than the Phase 1 outcomes. Although the reduction is within the range of those observed in competitors' Phase 3 trials, Intellia's treatment is seen as uniquely advantageous due to its potential as a one-time treatment, in contrast to competitors' treatments which require dosing from once monthly to daily. Despite this, the projected market share peak for NTLA-2002 has been adjusted downward, along with a more cautious view on the likelihood of success for NTLA-2001 in ATTR, suggesting that further validation of the platform is necessary.
The firm has adopted a more cautious stance on Intellia Therapeutics after evaluating the Phase 2 study results of NTLA-2002 in patients with hereditary angiodema (HAE), expressing incrementally negative sentiments.
Here are the latest investment ratings and price targets for $Intellia Therapeutics (NTLA.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月25日，多家华尔街大行更新了$Intellia Therapeutics (NTLA.US)$的评级，目标价介于18美元至90美元。
摩根士丹利分析师Terence Flynn维持买入评级，维持目标价57美元。
美银证券分析师Alec Stranahan首予买入评级，目标价65美元。
巴克莱银行分析师Gena Wang维持买入评级，维持目标价76美元。
贝雅分析师Jack Allen维持持有评级，并将目标价从24美元下调至18美元。
奥本海默控股分析师Jay Olson维持买入评级，维持目标价70美元。
此外，综合报道，$Intellia Therapeutics (NTLA.US)$近期主要分析师观点如下：
Intellia Therapeutics最新的数据显示，NTLA-2002相位2试验针对HAE在6月的EAACI会议上报告，表明攻击减少力度不如第1相位的结果显著。尽管减少幅度在竞争对手第3相位试验中观察到的区间内，但由于其作为一次性治疗的潜力，Intellia的治疗被认为具有独特优势，这与竞争对手的治疗方案相反，后者需要每月一次至每天的剂量。尽管如此，NTLA-2002预计的市场份额峰值已经下调，同时对NTLA-2001在ATTR方面的成功可能性持更为谨慎的看法，表明需要进一步验证该平台。
在评估NTLA-2002对患有遗传性血管性水肿（HAE）患者的第2相研究结果后，该公司对Intellia Therapeutics采取了更加谨慎的态度，表达了逐渐消极的情绪。
以下为今日10位分析师对$Intellia Therapeutics (NTLA.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
